Valuation: Cantargia AB

Market Cap 390M 39.31M 35.1M 32.43M 29.39M 54.98M 3.73B 55.89M 154M 1.96B 148M 144M 6.16B P/E 2026 *
-2.2x
P/E 2027 * -2.16x
Enterprise Value 390M 39.31M 35.1M 32.43M 29.39M 54.98M 3.73B 55.89M 154M 1.96B 148M 144M 6.16B EV / Sales 2026 *
976x
EV / Sales 2027 * 10.8x
Free-Float
97.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.39%
1 week+5.97%
Current month-9.19%
1 month-7.79%
3 months-24.78%
6 months-63.25%
Current year-66.93%
1 week 1.27
Extreme 1.273
1.44
1 month 1.25
Extreme 1.25
1.79
Current year 1.25
Extreme 1.25
6.59
1 year 1.25
Extreme 1.25
6.59
3 years 1
Extreme 1
6.59
5 years 1
Extreme 1
21.66
10 years 1
Extreme 1
71.8
Manager TitleAgeSince
Chief Executive Officer 60 01/09/2025
Director of Finance/CFO 56 15/06/2023
Chief Tech/Sci/R&D Officer - 02/10/2025
Director TitleAgeSince
Chairman 66 01/01/2016
Director/Board Member 55 01/01/2018
Director/Board Member 66 01/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
6/22/26 A Buy

Chief Technology Officer

18,238 0.0073%
6/22/26 A Exercice

Director

-74,997 0.0302%
4/2/26 A Free

Chief Technology Officer

80,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%+5.97%-41.97%-65.05% 39.31M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.39%+2.77%+39.07%+120.29% 38.32B
Weighted average by Cap. +0.39%+2.73%+46.01%+142.82%

Financials

2026 *2027 *
Net sales 400K 40.29K 35.98K 33.24K 30.12K 56.36K 3.82M 57.29K 158K 2M 151K 148K 6.32M 36.05M 3.63M 3.24M 3M 2.71M 5.08M 345M 5.16M 14.27M 181M 13.63M 13.34M 569M
Net income -159M -15.97M -14.26M -13.18M -11.94M -22.34M -1.52B -22.71M -62.77M -794M -59.94M -58.66M -2.5B -151M -15.17M -13.54M -12.51M -11.34M -21.21M -1.44B -21.56M -59.6M -754M -56.91M -55.7M -2.38B
Net Debt - -
Projected Income Statement - Annual - Cantargia AB
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
22
Date Price Change Volume
23/10/26 SEK 1.384 +1.39% 838,582
22/10/26 SEK 1.365 +0.74% 898,943
21/10/26 SEK 1.355 +1.12% 1,367,233
20/10/26 SEK 1.340 +1.59% 913,852
19/10/26 SEK 1.319 +1.00% 597,432
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cantargia AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.384SEK
Average target price
8.250SEK
Spread / Average Target
+496.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cantargia AB
  1. Stock Market
  2. Stocks
  3. CANTA Stock